Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model

Company Bags $250m In Series A

18 Feb 2021

• By William Masters

In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.

Centessa Pharmaceuticals has launched with a first-of-its-kind model involving the merger of ten biotechs and $250m in series A backing. The new company was created through the merger of ten private biotechs, which will sit under the Centessa umbrella as subsidiaries.

Headed up by a couple of industry heavyweights, and founded by UK life sciences venture capital firm Medicxi, the stated goal is to create a new R&D model which cuts...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

23 May 2025

• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

22 May 2025

• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.